Double Medical Technology Inc. (SHE:002901)
China flag China · Delayed Price · Currency is CNY
38.70
-1.13 (-2.84%)
Sep 11, 2026, 3:04 PM CST

Double Medical Technology Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Operating Revenue
2,7082,5812,1191,5251,4281,989
Other Revenue
22.0819.8516.78.395.945.02
2,7302,6012,1361,5331,4341,994
Revenue Growth
14.63%21.79%39.30%6.91%-28.09%25.68%
Cost of Revenue
817.15826.15710.15541.52344.6319.12
Gross Profit
1,9131,7751,425991.61,0891,675
Selling, General & Admin
862.6844.75769.03690.5788.18746.94
Research & Development
338.93331.2306.87285.28256.72167.07
Other Operating Expenses
41.926.4110.98-2.5115.7727.52
Operating Expenses
1,2531,2041,093972.131,059957.77
Operating Income
660.52571.15332.519.4730.9717.45
Interest Expense
-4.57-6.18-6.49-7.16-3.1-0.55
Interest & Investment Income
30.6832.2144.7839.6537.2334.63
Currency Exchange Gain (Loss)
-11.2710.25-11.350.777.62-5.87
Other Non Operating Income (Expenses)
-0.83-1.67-0.16-0.54-0.32-0.2
EBT Excluding Unusual Items
674.54605.76359.2852.1972.33745.45
Impairment of Goodwill
-5.9-5.91-0.5-0.86-1.37-0.91
Gain (Loss) on Sale of Investments
106.5249.413.115.61.771.22
Gain (Loss) on Sale of Assets
0.360.620.270.3-1.73-0
Asset Writedown
-0.74-0.35-0.43-0.02-0.54-0.03
Legal Settlements
-1.5-2.8----19.1
Other Unusual Items
93.7583.366.6942.517775.88
Pretax Income
867.04730.04428.4199.72147.46802.51
Income Tax Expense
112.8893.1743.1213.437.89111.01
Earnings From Continuing Operations
754.16636.88385.2986.32109.57691.5
Minority Interest in Earnings
-45.46-37.25-28.49-27.36-17.01-18.19
Net Income
708.7599.63356.858.9692.56673.31
Net Income to Common
708.7599.63356.858.9692.56673.31
Net Income Growth
53.13%68.06%505.16%-36.30%-86.25%11.16%
Shares Outstanding (Basic)
409408415421421401
Shares Outstanding (Diluted)
410408415421421403
Shares Change
-0.35%-1.68%-1.49%0.10%4.35%0.52%
EPS (Basic)
1.731.470.860.140.221.68
EPS (Diluted)
1.731.470.860.140.221.67
EPS Growth
53.67%70.93%514.29%-36.36%-86.83%10.60%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Jan '22
Free Cash Flow
699.94697.83171.84-231.82-156.63438.15
Free Cash Flow Per Share
1.711.710.41-0.55-0.371.09
Dividend Per Share
0.6000.6000.5000.250-0.500
Dividend Growth
20.00%20.00%100.00%---37.50%
Gross Margin
70.07%68.23%66.75%64.68%75.97%84.00%
Operating Margin
24.19%21.96%15.57%1.27%2.15%35.97%
Profit Margin
25.96%23.05%16.71%3.85%6.45%33.76%
Free Cash Flow Margin
25.64%26.83%8.05%-15.12%-10.92%21.97%
EBITDA
787.03696.35447.72121.28117.12782.07
EBITDA Margin
28.83%26.77%20.96%7.91%8.17%39.22%
D&A For EBITDA
126.5125.2115.22101.8186.2264.62
EBIT
660.52571.15332.519.4730.9717.45
EBIT Margin
24.19%21.96%15.57%1.27%2.15%35.97%
Effective Tax Rate
13.02%12.76%10.06%13.44%25.70%13.83%
Revenue as Reported
2,7302,6012,1361,5331,4341,994